Table 1.
Recipient characteristics
| PTHU
|
FX
|
NFX
|
P-value | |||
|---|---|---|---|---|---|---|
| FN | FC | OB | CT | NPTHU | ||
| Recipients, n | 15 | 11 | 12 | 13 | 42 | |
| Baseline uric acid (mg/g Cr) | 8.4±1.0*,† | 7.5±1.5*,† | 7.7±0.6*,† | 6.3±1.2 | 5.6±1.0 | 0.02 |
| Achievement of target uric acid, n (%) | 0 | 2 (18%) | 0 | 4 (31%) | 24 (57%) | <0.01 |
| Age (years) | 52±12 | 44±10 | 51±18 | 57±9 | 49±14 | 0.21 |
| Male, n (%) | 13 (87%) | 10 (91%) | 9 (82%) | 11 (85%) | 24 (57%) | 0.055 |
| Diabetes, n (%) | 4 (27%) | 1 (9%) | 3 (25%) | 1 (8%) | 12 (29%) | 0.43 |
| Baseline eGFR (mL/min/1.73 m2) | 43.2±13.1 | 36.7±15.2 | 52.7±24.8 | 41.3±11.3 | 50.8±15.1 | 0.03 |
| BMI (kg/m2) | 22.2±5.0 | 22.6±4.7 | 20.2±2.3 | 22.1±3.7 | 22.5±3.5 | 0.53 |
| Systolic blood pressure (mmHg) | 117±7 | 119±11 | 121±13 | 128±13 | 119±11 | 0.30 |
| Time after transplantation (years) | 5.8±3.2 | 7.1±4.5 | 6.8±3.8 | 5.8±3.1 | 5.0±3.4 | 0.33 |
| Cadaver donor, n (%) | 0 | 0 | 1 (8%) | 1 (8%) | 1 (2%) | 0.59 |
| Blood type incompatible, n (%) | 4 (27%) | 5 (45%) | 4 (33%) | 6 (46%) | 12 (29%) | 0.66 |
| Tacrolimus-based IS, n (%) | 12 (87%) | 8 (73%) | 9 (75%) | 9 (81%) | 38 (90%) | 0.51 |
| Trough level of tacrolimus (ng/mL) | 5.0±1.0 | 5.4±1.5 | 5.4±1.2 | 5.0±1.2 | 5.6±1.3 | 0.47 |
| MMF-based IS, n (%) | 13 (87%) | 8 (64%) | 11 (92%) | 9 (82%) | 40 (95%) | 0.38 |
| MMF dose (mg) | 1,173±277 | 1,000±289 | 932±162 | 1,023±284 | 1,081±51 | 0.38 |
| mPSL dose (mg) | 2.2±1.1 | 2.7±1.0 | 2.6±2.6 | 2.2±0.6 | 2.0±0.9 | 0.45 |
| ARB treatment, n (%) | 11 (73%)* | 11 (100%)* | 8 (67%) | 9 (69%) | 17 (40%) | <0.01 |
| CCB treatment, n (%) | 7 (47%) | 8 (73%)* | 7 (58%)* | 9 (69%)* | 10 (24%) | <0.01 |
| PPI treatment, n (%) | 11 (73%) | 8 (73%) | 7 (58%) | 11 (85%) | 33 (79%) | 0.60 |
| Statin treatment, n (%) | 1 (7%) | 5 (45%)* | 4 (33%) | 3 (23%) | 4 (10%) | 0.03 |
| ESA treatment, n (%) | 3 (20%)* | 2 (18%)* | 0 | 3 (23%)* | 0 | 0.02 |
Notes: Values are shown as the mean ± standard deviation or n (%).
*
P<0.05 versus NPTHU;
†
P<0.05 versus CT.
Abbreviations: Cr, creatinine; PTHU, post-transplant hyperuricemia; NPTHU, non-post-transplant hyperuricemia; FX, febuxostat group; NFX, non-febuxostat group; FN, newly treated with febuxostat; FC, conversion to febuxostat; OB, observation without intervention; CT, continued conventional therapy; eGFR, estimated glomerular filtration rate; BMI, body mass index; IS, immunosuppressant; MMF, mycophenolate mofetil; mPSL, methylprednisolone; ARB, angiotensin II type 1 receptor blocker; CCB, calcium channel blocker; PPI, proton pump inhibitor; ESA, erythropoiesis-stimulating agent.